



India

ADD (no change)

Consensus ratings*: Buy 3 Hold 0 Sell 0

Current price:	Rs769
Target price:	Rs1,010
Previous target:	Rs1,010
Up/downside:	31.3%
InCred Research / Consensus:	5.2%
Reuters:	THYO.NS
Bloomberg:	THYROCAR IN
Market cap:	US\$477m
	Rs40,763m
Average daily turnover:	US\$0.8m
	Rs71.0m
Current shares o/s:	53.0m
Free float:	28.9%

*Source: Bloomberg

Key changes in this note

- Cut FY26F EPS by 3%.
- Stock inclusion in high conviction ideas list.
- Introduce FY27F estimates and roll forward our valuation.



Source: Bloomberg

Price performance	1M	3M	12M
Absolute (%)	4.6	(2.4)	16.6
Relative (%)	1.9	(7.2)	7.4

Major shareholders	% held
Promoters	71.1
Nippon India Small Cap Fund	6.7
ICICI Prudential Pharma Healthcare	4.2

Research Analyst(s)

Yogesh SONI

T (91) 22 4161 1566

E yogesh.soni@incredresearch.com

Thyrocare Technologies Ltd.

Strong performance; beat on margin front

- Robust 4QFY25 performance which beat expectations led by volume. The topline grew by 21% YoY and margin was up 1,100bp YoY.
- Acquisition strategy to continue in FY26F as well with a dedicated allocation of Rs150-200m. Tanzania in a nascent stage but doubling revenue each quarter.
- Cut FY26F EPS by 3% due to the revised tax rate. Maintain ADD rating on the stock with a TP of Rs1,010 and included it in our high conviction ideas list.

All-round performance beat

The 4QFY25 performance of Thyrocare Technologies (Thyrocare) beat our/Bloomberg consensus estimates. Revenue growth at 21% YoY/13% QoQ (our estimate of 16%) was mostly volume-led (sample growth of 15% YoY). Realization growth (revenue/sample) during the quarter was 6%. The radiology business growth slowed (7% YoY vs. double-digit growth in the last four quarters), but radiology business margin improvement (+300bp QoQ at 20.5%) offset the same. The EBITDA margin (~35%) improvement was significant at 1,100bp YoY due to gross margin improvement (~400bp), operating leverage benefit (~200bp), and reduced provisioning (~400bp). NHL, with the recent substantial price hike, has reached a sustainable gross margin level (~80%). Thyrocare expects to outperform the pathology industry by growing at a mid-teen rate (even on a high base) and maintain the FY25 EBITDA margin level (30.7%).

Acquisition strategy to fill the gap

In FY25, Thyrocare spent Rs113m for the acquisition of Polo Labs and Vimta Labs with an aim to expand the footprint in North India, and Andhra Pradesh & Telangana, respectively. These acquisitions have started contributing to the performance; inorganic growth during 4Q was 2%. Thyrocare's strategic acquisition spree is expected to continue in FY26F as well. It is focusing on acquisitions in Gujarat, Rajasthan and the northeast region for which it has allocated Rs150-200m.

International business – Tanzania still in a nascent stage

Thyrocare's international venture in Tanzania is still in a nascent stage. The lab has partnered with 150+ healthcare facilities (vs. 100+ in 3QFY25). The business is doubling revenue every quarter and in 4Q it garnered a revenue of Rs6m vs. Rs3.5m in 3QFY25.

Maintain ADD rating with unchanged target price of Rs1,010

We have introduced FY27F estimates and rolled forward our valuation to the same period. We have marginally reduced FY26F EPS by 3% to reflect the revised tax rate. The stock is currently trading near SD-1 valuation, offering a suitable entry point. We maintain ADD rating on the stock with an unchanged target price of Rs1,010 and included it in our high conviction ideas list. Any slowdown in volume is a downside risk.

Financial Summary	Mar-23A	Mar-24A	Mar-25A	Mar-26F	Mar-27F
Revenue (Rsm)	5,267	5,719	6,874	7,817	8,768
Operating EBITDA (Rsm)	1,390	1,526	2,111	2,427	2,771
Net Profit (Rsm)	645	707	915	1,137	1,463
Core EPS (Rs)	14.8	15.4	19.7	24.3	28.7
Core EPS Growth	(55.6%)	4.6%	27.7%	23.3%	18.2%
FD Core P/E (x)	52.08	49.81	39.01	31.66	26.76
DPS (Rs)	18.0	18.0	21.0	21.0	21.0
Dividend Yield	2.34%	2.34%	2.73%	2.73%	2.73%
EV/EBITDA (x)	28.24	25.69	18.41	16.08	13.96
P/FCFE (x)	48.81	44.79	31.49	32.73	26.12
Net Gearing	(28.2%)	(29.4%)	(35.1%)	(33.9%)	(39.2%)
P/BV (x)	7.63	7.74	7.46	7.44	7.01
ROE	14.8%	15.4%	19.5%	23.5%	27.0%
% Change In Core EPS Estimates				(2.53%)	(1.24%)
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 1: Financial summary

(Rs m)	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	Y-o-Y (%)	Q-o-Q (%)
Revenue	1,359	1,349	1,480	1,347	1,543	1,569	1,774	1,660	1,872	21%	13%
Consumption of raw materials	418	381	436	384	466	455	510	452	495	6%	10%
as % of sales	30.7%	28.2%	29.5%	28.5%	30.2%	29.0%	28.7%	27.2%	26.4%		
Employee costs	218	222	235	233	237	260	270	274	259	9%	-6%
as % of sales	16.1%	16.4%	15.9%	17.3%	15.3%	16.6%	15.2%	16.5%	13.8%		
Other expenditure	412	344	398	384	473	401	486	439	465	-2%	6%
as % of sales	30.3%	25.5%	26.9%	28.5%	30.7%	25.5%	27.4%	26.5%	24.9%		
EBITDA	311	402	411	347	367	453	508	495	653	78%	32%
Margin (%)	22.9%	29.8%	27.7%	25.7%	23.8%	28.9%	28.6%	29.8%	34.9%		
Depreciation	108	98	107	135	131	114	131	171	138		
Other income	37	10	22	27	35	36	26	40	46		
Interest	7	9	11	11	11	10	8	6	7		
PBT	234	305	315	229	260	366	396	358	554	113%	55%
Total tax	48	77	79	52	57	96	104	90	256		
Tax rate (%)	20.3%	25.1%	25.2%	22.6%	22.0%	26.2%	26.2%	25.0%	46.2%		
PAT before MI	186	228	235	177	203	270	292	269	298	47%	11%
Minority interest (MI)	3	1	4	7	4	-1	0	-2	-6		
Adj. PAT before extraordinary items	189	229	239	184	207	269	292	267	292	41%	9%
Extraordinary expenses	-65	-57	-35	-31	-29	-27	-25	-77	-76		
Reported PAT	125	172	203	153	178	242	267	190	216	21%	13%
No. of shares	53	53	53	53	53	53	53	53	53		
EPS	3.6	4.3	4.5	3.5	3.9	5.1	5.5	5.0	5.5		

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 2: Margin break-up

(in %)	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	Y-o-Y (bp)	Q-o-Q (bp)
Gross	69%	72%	71%	71%	70%	71%	71%	73%	74%	376	78
EBITDA	23%	30%	28%	26%	24%	29%	29%	30%	35%	1109	507
Adj. PAT	14%	17%	16%	14%	13%	17%	16%	16%	16%	218	-51
Effective tax rate	20%	25%	25%	23%	22%	26%	26%	25%	46%	2425	2120

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 3: Revenue break-up

(Rs m)	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	Y-o-Y (%)	Q-o-Q (%)
Diagnostic testing services	1,232	1,219	1,368	1,224	1,411	1,432	1,619	1,519	1,727	22%	14%
% total revenue	91.3%	90.4%	92.4%	90.9%	91.5%	91.3%	91.3%	91.5%	92.3%		
Imaging services	111	113	117	119	128	130	142	134	137	7%	2%
% total revenue	8.2%	8.4%	7.9%	8.8%	8.3%	8.3%	8.0%	8.1%	7.3%		
Others	6	17	-5	5	4	7	13	7	8	108%	13%
Total revenue	1,349	1,349	1,480	1,347	1,543	1,569	1,774	1,660	1,872	21%	13%

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 4: Actuals versus estimates (Rs m)

	Actuals	IncRed Estimates	Variance (%)	Bloomberg Estimates	Variance (%)
Revenue	1,872	1,789	4.6	1,846	1.4
EBITDA	653	507	28.8	441	48.2
Margin (%)	34.9	28.3		23.9	
Adj. PAT	292	272	7.4	236	23.6

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 5: Our revised earnings estimates (Rs m)


Particulars	FY26F		
	Old	New	% change
Revenue	7,732	7,817	1.1
EBITDA	2,246	2,427	8.0
Margin	29.1%	31.0%	
PAT	1,176	1,137	(3.3)

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 6: After the recent price correction, Thyrocare trades at an attractive valuation - near SD-1, providing a sweet entry point



BY THE NUMBERS



Profit & Loss

(Rs mn)	Mar-23A	Mar-24A	Mar-25A	Mar-26F	Mar-27F
Total Net Revenues	5,267	5,719	6,874	7,817	8,768
Gross Profit	3,634	4,052	4,963	5,628	6,357
Operating EBITDA	1,390	1,526	2,111	2,427	2,771
Depreciation And Amortisation	(387)	(470)	(553)	(610)	(675)
Operating EBIT	1,003	1,056	1,558	1,817	2,096
Financial Income/(Expense)	(24)	(42)	(31)	(40)	(45)
Pretax Income/(Loss) from Assoc.	13	17	(7)	(15)	(15)
Non-Operating Income/(Expense)	84	94	148	130	150
Profit Before Tax (pre-EI)	1,076	1,125	1,669	1,892	2,186
Exceptional Items	(189)	(152)	(207)	(221)	(85)
Pre-tax Profit	887	972	1,462	1,671	2,101
Taxation	(242)	(265)	(547)	(534)	(638)
Exceptional Income - post-tax					
Profit After Tax	645	707	915	1,137	1,463
Minority Interests					
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	645	707	915	1,137	1,463
Recurring Net Profit	782	818	1,045	1,287	1,522
Fully Diluted Recurring Net Profit	782	818	1,045	1,287	1,522

Cash Flow

(Rs mn)	Mar-23A	Mar-24A	Mar-25A	Mar-26F	Mar-27F
EBITDA	1,390	1,526	2,111	2,427	2,771
Cash Flow from Invt. & Assoc.					
Change In Working Capital	58	302	(125)	(294)	(214)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow	(105)	(58)	100	120	120
Net Interest (Paid)/Received	(24)	(42)	(31)	(40)	(45)
Tax Paid	(26)	(51)	17	(418)	(673)
Cashflow From Operations	1,293	1,676	2,072	1,795	1,959
Capex	(416)	(609)	(449)	(350)	(400)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments			(113)	(200)	
Other Investing Cashflow	26	(304)			
Cash Flow From Investing	(390)	(913)	(562)	(550)	(400)
Debt Raised/(repaid)	(68)	147	(216)		
Proceeds From Issue Of Shares					
Shares Repurchased					
Dividends Paid	(794)	(953)	(953)	(1,112)	(1,112)
Preferred Dividends					
Other Financing Cashflow		(42)			
Cash Flow From Financing	(862)	(848)	(1,169)	(1,112)	(1,112)
Total Cash Generated	41	(85)	341	133	447
Free Cashflow To Equity	835	910	1,294	1,245	1,559
Free Cashflow To Firm	927	805	1,541	1,285	1,604

SOURCE: INCRED RESEARCH, COMPANY REPORTS

BY THE NUMBERS...cont'd

Balance Sheet					
(Rs mn)	Mar-23A	Mar-24A	Mar-25A	Mar-26F	Mar-27F
Total Cash And Equivalents	1,508	1,766	1,918	1,930	2,428
Total Debtors	851	435	730	782	964
Inventories	277	475	465	704	877
Total Other Current Assets	94	109	263	313	263
Total Current Assets	2,729	2,785	3,377	3,728	4,532
Fixed Assets	1,952	2,044	1,983	1,723	1,448
Total Investments	221	256	242	242	242
Intangible Assets	1,003	1,040	1,131	1,131	1,131
Total Other Non-Current Assets	422	313	195	195	195
Total Non-current Assets	3,598	3,654	3,550	3,290	3,015
Short-term Debt		107			
Current Portion of Long-Term Debt					
Total Creditors	240	401	762	758	702
Other Current Liabilities	459	307	456	506	655
Total Current Liabilities	699	815	1,218	1,264	1,357
Total Long-term Debt		109			
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	276	238	239	239	239
Total Non-current Liabilities	276	347	239	239	239
Total Provisions					
Total Liabilities	975	1,163	1,457	1,503	1,595
Shareholders Equity	5,343	5,268	5,468	5,477	5,813
Minority Interests	9	9	3	218	383
Total Equity	5,352	5,276	5,471	5,695	6,196

Key Ratios					
	Mar-23A	Mar-24A	Mar-25A	Mar-26F	Mar-27F
Revenue Growth	(10.6%)	8.6%	20.2%	13.7%	12.2%
Operating EBITDA Growth	(40.8%)	9.8%	38.3%	15.0%	14.2%
Operating EBITDA Margin	26.4%	26.7%	30.7%	31.0%	31.6%
Net Cash Per Share (Rs)	28.46	29.27	36.20	36.46	45.84
BVPS (Rs)	100.85	99.43	103.17	103.44	109.78
Gross Interest Cover	42.66	25.15	51.08	45.41	46.58
Effective Tax Rate	27.3%	27.3%	37.4%	32.0%	30.4%
Net Dividend Payout Ratio	88.5%	84.7%	66.7%	58.8%	50.9%
Accounts Receivables Days	61.79	41.04	30.92	35.29	36.35
Inventory Days	58.36	82.32	89.84	97.47	119.61
Accounts Payables Days	45.35	70.18	111.10	126.78	110.51
ROIC (%)	26.3%	27.1%	42.0%	51.2%	58.5%
ROCE (%)	18.9%	19.5%	28.4%	32.5%	35.3%
Return On Average Assets	17.8%	18.3%	25.4%	27.7%	30.6%

SOURCE: INCRED RESEARCH, COMPANY REPORTS

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd. (formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. While every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which is believed to be accurate and complete and obtained through reliable public or other non-confidential sources at the time made (information barriers and other arrangements may be established, where necessary, to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short-term views, etc.) that are inconsistent with and reach a different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

Research Analyst or his/her relative(s) or InCred Research Services Private Limited or our associate may have any financial interest in the subject company.

Research Analyst or his/her relatives or InCred Research Services Limited or our associates may have actual or beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the Research Report.

Research Analyst or his/her relative or InCred Research Services Private Limited or our associate entities may have any other material conflict of interest at the time of publication of the Research Report.

In the past 12 months, IRSPL or any of its associates may have:

- a) Received any compensation/other benefits from the subject company,
- b) Managed or co-managed public offering of securities for the subject company,
- c) Received compensation for investment banking or merchant banking or brokerage services from the subject company,
- d) Received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company

We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.

Research Analyst may have served as director, officer, or employee in the subject company.

We or our research analyst may engage in market-making activity of the subject company.

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based on any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in this report and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.

Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

InCred Research Services Private Limited

Research Analyst SEBI Registration Number: INH000011024

Registered Office: Unit No 1203, 12th Floor, B Wing, The Capital, C-70, G Block, BKC, Bandra (E), Mumbai – 400051

Phone: +91-22-6844-6100

Corporate Office: 05th floor, Laxmi Towers, Plot No. C-25, G Block, Bandra – Kurla Complex, Bandra (East), Mumbai – 400051

Phone: +91-22-4161-1500

Name of the Compliance Officer: Mr. Yogesh Kadam

Email ID: compliance@incredresearch.com, Phone No: +91-22-41611539

For any queries or grievances, you may contact the Grievance Officer.

Name of the Grievance Officer: Mr. Rajarshi Maitra

Phone no. +91-022-41611546

Email ID: rajarshi.maitra@incredresearch.com

CIN: U74999MH2016PTC287535

Recommendation Framework**Stock Ratings**

Definition:

- Add** The stock's total return is expected to exceed 10% over the next 12 months.
- Hold** The stock's total return is expected to be between 0% and positive 10% over the next 12 months.
- Reduce** The stock's total return is expected to fall below 0% or more over the next 12 months.

The total expected return of a stock is defined as the sum of the: (i) percentage difference between the target price and the current price and (ii) the forward net dividend yields of the stock. Stock price targets have an investment horizon of 12 months.

Sector Ratings

Definition:

- Overweight** An Overweight rating means stocks in the sector have, on a market cap-weighted basis, a positive absolute recommendation.
- Neutral** A Neutral rating means stocks in the sector have, on a market cap-weighted basis, a neutral absolute recommendation.
- Underweight** An Underweight rating means stocks in the sector have, on a market cap-weighted basis, a negative absolute recommendation.

Country Ratings

Definition:

- Overweight** An Overweight rating means investors should be positioned with an above-market weight in this country relative to benchmark.
- Neutral** A Neutral rating means investors should be positioned with a neutral weight in this country relative to benchmark.
- Underweight** An Underweight rating means investors should be positioned with a below-market weight in this country relative to benchmark.